Member Info for mulledwine

Positive outcome for VR040 in Parkinson's trial Statistically significant improvement in symptoms Rapid onset of therapeutic benefit Chippenham, UK - 16 November 2010: Vectura Group plc ("Vectura"; LSE: VEC) today announces positive data from a Phase II clinical study for its inhalation product, VR040, for the treatment of "off" episodes (periods of inability to control movement) in patients with fluctuating Parkinson's disease. VR040 is Vectura's proprietary formulation of apomorphine, delivered to the bloodstream by inhalation through the lungs using the Company's proprietary dry powder inhalation (DPI) technology. VR040 was designated an orphan drug by the European Medicines Agency (EMA) and is being developed using the EMA scientific advice procedure. The results of the study demonstrate that VR040 improves the control of movement in patients with Parkinson's disease. VR040 produced clinically relevant and statistically significant improvement, compared with placebo (p=0.023), of the Unified Parkinson's Disease Rating Scale Part III (UPDRS III), a measure of a patient's ability to control movement (see Notes for editors). VR040 also reduced the time patients were in an "off" state by over 2 hours, a change considered by the investigators to be highly clinically relevant, although not statistically significant (p=0.078), when compared with placebo in the relatively small number of patients tested. The mean onset of therapeutic benefit was rapid, with patients converting to an "on" state in less than 9 minutes after taking VR040, with some patients responding just one minute after receiving their dose. VR040 was well tolerated with no reports of severe adverse events. Fifty-five patients, diagnosed with fluctuating idiopathic Parkinson's disease, were randomised to receive either placebo or VR040. Patients were rapidly titrated to a dose of VR040 that elicited a therapeutic response and continued to use this dose in the home setting to treat "off" episodes. Dr Donald Grosset, BSc (Hons), MBChB, MD, Consultant Neurologist in the Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK and Principal Investigator of the study, commented: "The study was a first opportunity to evaluate inhaled apomorphine in the home environment with patients reporting clinically significant reductions in their mean daily off time. It is reassuring to see that the safety and therapeutic benefit of VR040 have now been reproduced across three separate trials in 126 Parkinson's disease patients." Dr Chris Blackwell, Chief Executive of Vectura, added: "This study confirms the potential therapeutic benefit of VR040 to Parkinson's patients, and in three separate studies, that it is a safe, easy to use and non-invasive treatment. These data will also be of value in ongoing discussions with prospective licensing pa

http://www.investegate.co.uk/Article.aspx?id=201011160701052303W

http://www.investegate.co.uk/Article.aspx?id=201011160702012437W

http://www.investegate.co.uk/Article.aspx?id=201011150700091597W

http://www.investegate.co.uk/Article.aspx?id=201011150700051464W

ksarar - I am aware of them both and had looked at IOM before but didnt have the funds at the time nor now !....Whats your trading plan for either? Not sure of the relevant daes for each Company but if your plan is not long than possibly buy into IOM for the results - take the increase assuming there is one and then sell and take it to BAO - However if you looking to go long then hmmmmm why not go with IOM also - if you are like me just now perhaps your portfolio is heavy on the oil and miners side so a little diversification into IOM might not be a bad thing.

Stake building? 3 x 100k and 1 x 50k stock purchases in last 2 days while price has dropped from latest high

Dattles and Mellon are also on the board of RGP which has just bought 3.18% of SOLG. They get around. Have a look at RGP - They have fingers in many pies.

Thought I would post the RNS to stop bulldozer going stir crazy!

http://www.investegate.co.uk/Article.aspx?id=20101112103135M1224

http://www.investegate.co.uk/Article.aspx?id=20101112093007P6E83

http://www.investegate.co.uk/Article.aspx?id=201011120940400860W

http://www.investegate.co.uk/Article.aspx?id=201011120730030830W

However they are, I think hinting at cash may be needed - Provided a satisfactory investment climate is created in Zimbabwe and the Zimbabwean indigenization requirements and obligations are finally clarified and economically viable, Caledonia intends to make the significant capital investments in Blanket, which are required to sustain gold production at 40,000 ounces per annum.

May be some upside here today - increased gold production and at less cost Commenting on the quarter's performance, Stefan Hayden, President and CEO said: "I am pleased to report that gold production at the Blanket mine was 45% higher than in the previous quarter. This was an outstanding and highly commendable performance by the Blanket and Caledonia management teams. This increase in production was also due to the implementation of a revised mine plan, improved recoveries from the metallurgical plant and the installation of the first standby generator in late June. The generator has allowed underground operations to continue during interruptions to the normal electricity supply. Blanket's cash costs decreased significantly from US$816 per ounce in the second quarter to US$651 per ounce in the third quarter. We expect that Blanket's cash costs will continue to decrease as production increases to an annualized level of approximately 40,000 ounces of gold per annum by the end of 2010, following the commissioning of the No. 4 Shaft Expansion Project at the end of third quarter.

Firm Placing and Placing and Open Offer at 15 pence per share to raise up to £21 million The Board of Corac, the intellectual property, engineering and licensing company specialising in compressor technology, announces a proposed Placing and Open Offer of up to 140,000,596 New Shares at 15 pence per New Share to raise gross proceeds of up to approximately £21 million (approximately £19.7 million net of expenses).

http://www.investegate.co.uk/Article.aspx?id=201011120700130702W

Divi restored.

Hornby Plc, the international models and collectables group, today announces its half year results for the six months ended 30 September 2010. Hornby owns a number of model railway and slot car brands, Airfix models, Humbrol paints and Corgi die-cast models. · Turnover up 2% to £25.5 million · Statutory pre-tax profit £0.5 million (£0.7 million 30 September 2009) · Distribution partnership agreed with The Royal Mint · Disney/Pixar Toy Story 3 Licence performing well in Scalextric and Hornby · Hornby Heritage Visitor Centre opened in Kent · Net debt reduced to £10.8 million (£14.7 million 30 September 2009) · Interim Dividend of 1.7p restored Frank Martin, Chief Executive of Hornby said, " Demand for our products remains strong. Our core ranges of model railways, Scalextric, Airfix and Corgi are all performing well. Hornby is in good financial health and we are pleased that our suppliers have taken steps to increase volumes. In addition, we have continued our strategy to diversify our supplier base. We have brought on stream a significant additional source of model railway manufacturing, thus further reducing our dependency on our largest supplier. " We are delighted there is strong interest in our London 2012 Olympic ranges. Our involvement in London 2012 has resulted in a landmark distribution agreement, recently signed, with The Royal Mint. Under this agreement we will distribute The Royal Mint range of London 2012 sports collectable coins via our mass market and hobby retailers. We expect that this agreement will form the basis of a long term relationship between Hornby and The Royal Mint. " Ahead of the Christmas season, we are well placed. We have strong retail relationships and our product ranges appeal to a wide cross section of hobbyists and enthusiasts. Despite the economic conditions, the team is really excited about the prospects for the Group. We are confident that, from here, we can drive the performance of the Group forward ."

http://www.investegate.co.uk/Article.aspx?id=201011120700080520W